Answers are grounded in this paper and cite their sources.
Investigations of the open system behavior of reversible dead-end inhibitors were carried out by means of computer simulations and experimental studies. The results from both approaches indicate that substrate-competitive inhibition may often be an inappropriate basis for design of potential therapeutic agents. The use of uncompetitive (also called anticompetitive) inhibitors in this role is likely to be far more effective. Chemical analogs of pathogen-specific enzymic reaction products rather than analogs of substrates provide a promising basis for the systematic design of such uncompetitive inhibitors.
No takes yet. Share an insight, caveat, or question.
Westley et al. (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: